Related Experiment Video
Updated: Aug 1, 2025
Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Immunoinformatics-guided design of a multi-valent vaccine against Rotavirus and Norovirus (ChRNV22)
Amanda de Oliveira Matos1, Thaís Cristina Vilela Rodrigues2, Sandeep Tiwari3
1Laboratory of Mucosal Immunology and Immunoinformatics (LIM), Institute of Tropical Pathology and Public Health, Federal University of Goiás (UFG), Goiânia, 746050-050, Brazil.
Insights
A novel chimeric vaccine, ChRNV22, was designed using immunoinformatics to combat Rotavirus (RV) and Norovirus (NV) acute gastroenteritis (AG). This multi-epitope vaccine shows promise for preventing severe AG in children globally.
Area of Science:
- Immunology
- Vaccinology
- Computational Biology
Background:
- Rotavirus (RV) and Norovirus (NV) are leading causes of acute gastroenteritis (AG), particularly in children, leading to significant mortality and morbidity.
- Current anti-RV vaccines are attenuated with variable efficacy, especially in developing nations, and no NV vaccine is currently licensed.
- The substantial global burden of AG necessitates novel vaccine strategies targeting both RV and NV.
Purpose of the Study:
- To computationally design a multi-epitope vaccine (ChRNV22) targeting prevalent genotypes of Rotavirus and Norovirus.
- To predict and assemble immunogenic epitopes from key viral proteins into a single chimeric construct.
- To evaluate the potential immunogenicity and safety of the designed vaccine candidate through in silico simulations.
Main Methods:
- Utilized immunoinformatics tools to predict epitopes from 17 prevalent RV and NV genotypes, focusing on structural proteins (NV's VP1, RV's VP4, VP6, VP7).
- Assembled selected epitopes into a chimeric protein (ChRNV22), incorporating adjuvant sequences (tetanus toxin P2, RV NSP4).
- Performed in silico simulations to assess immune response (Th1-bias) and vaccine safety (host-homology, allergenicity, toxicity).
Main Results:
- ChRNV22 was designed as a multi-epitope vaccine targeting diverse RV and NV genotypes.
- In silico analysis predicted ChRNV22 to possess strong immunogenic properties, including a favorable Th1-biased immune response.
- Computational safety assessments indicated no significant host-homologous, allergenic, or toxic regions within the vaccine construct.
Conclusions:
- The immunoinformatics-designed ChRNV22 vaccine candidate demonstrates potential for broad protection against Rotavirus and Norovirus acute gastroenteritis.
- The in silico findings suggest ChRNV22 is a promising candidate for further in vivo evaluation and development.
- This approach offers a novel strategy for creating effective vaccines against common viral gastroenteritis agents.
Abstract:
Rotavirus (RV) and Norovirus (NV) are the main viral etiologic agents of acute gastroenteritis (AG), a serious pediatric condition associated with significant death rates and long-term complications. Anti-RV vaccination has been proved efficient in the reduction of severe AG worldwide, however, the available vaccines are all attenuated and have suboptimal efficiencies in developing countries, where AG leads to substantial disease burden. On the other hand, no NV vaccine has been licensed so far. Therefore, we used immunoinformatics tools to develop a multi-epitope vaccine (ChRNV22) to prevent severe AG by RV and NV. Epitopes were predicted against 17 prevalent genotypes of four structural proteins (NV's VP1, RV's VP4, VP6 and VP7), and then assembled in a chimeric protein, with two small adjuvant sequences (tetanus toxin P2 epitope and a conserved sequence of RV's enterotoxin, NSP4). Simulations of the immune response and interactions with immune receptors indicated the immunogenic properties of ChRNV22, including a Th1-biased response. In silico search for putative host-homologous, allergenic and toxic regions also indicated the vaccine safety. In summary, we developed a multi-epitope vaccine against different NV and RV genotypes that seems promising for the prevention of severe AG, which will be further assessed by in vivo tests.
